A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 08 May 2017
At a glance
- Drugs RG 4733 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 22 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 16 Jan 2013 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Nov 2012 Planned end date changed from 1 Jul 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.